Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum MERUS LABS INTERNATIONAL INC T.MSL

"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."

TSX:MSL - Post Discussion

MERUS LABS INTERNATIONAL INC > Bruce Campbell on BNN
View:
Post by lscfa on Jun 15, 2016 1:29pm

Bruce Campbell on BNN

Minutes ago....is sticking with it....cheap valuation
Comment by retiredcf on Jun 17, 2016 8:28am
First stock in the clip. GLTA https://www.bnn.ca/Shows/Market-Call.aspx MSL-T 2016-06-15 PAST TOP PICK Bruce Campbell (1)   (A Top Pick June 1/15. Down 49.05%.) It was caught up in the Valeant downdraft for the group. This is non-US; it is all Canada or Europe. Very cheap. Made a couple of acquisitions. Doesn’t have a stretched balance sheet. Hasn’t bought drugs that have had price ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities